Nasdaq nmra.

Current. -$0.75. 1 Month Ago. -$0.75. 3 Months Ago. N/A. Neumora Therapeutics Inc. analyst estimates, including NMRA earnings per share estimates and analyst recommendations.NASDAQ: NMRA · IEX Real-Time Price · USD. Add to Watchlist 11.92 +0.01 (0.08%) Nov 24, 2023, 4:30 PM EST - Market closed. Overview; Financials; ... Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for NMRA stock stock is $22, which predicts an increase of 84.56%. The lowest target is $18 …Sep 26, 2023 · Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar Oct 18, 2023 · Christoph Burgstedt/iStock via Getty Images. Company logo. I started a long position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) last week with a 4.2% portfolio allocation.This recent central ... WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.

The latest Neumora Therapeutics stock prices, stock quotes, news, and NMRA history to help you invest and trade smarter. ... (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company ...Andrey Tolkachev/iStock via Getty Images. Neumora Therapeutics ( NASDAQ: NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer ...WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult …

WATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the ...

Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Neumora Therapeutics, Inc. Common Stock (NMRA) Pre-Market Stock Quotes - Nasdaq ...Neumora Therapeutics (NASDAQ: NMRA) is owned by 23.77% institutional shareholders, 65.44% Neumora Therapeutics insiders, and 10.79% retail investors. Amgen Inc is the largest individual Neumora Therapeutics shareholder, owning 35.37M shares representing 23.16% of the company. Amgen Inc's Neumora Therapeutics shares are currently valued …Insiders and Institutions Are Buying These Robot Stocks. This page (NASDAQ:NMRA) was last updated on 11/24/2023 by MarketBeat.com Staff. Adding. Choose a ...Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.

NVDA. NVIDIA Corporation Common Stock. $449.995 +1.295 +0.29%. Neumora Therapeutics, Inc. Common Stock (NMRA) Advanced Charting - Nasdaq offers …

Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.

The latest Neumora Therapeutics stock prices, stock quotes, news, and NMRA history to help you invest and trade smarter ... Nasdaq Live · World Map · The word ...14 Sep 2023 ... Home · News; NMRA. Neumora Therapeutics Inc. - NMRA STOCK NEWS. IMPACT. SENTIMENT. 11/27/2023 07:00 AM. NMRA : Nasdaq.Sep 14, 2023 · 1 Trading Held Add to Watchlist Add to Portfolio Quotes Summary Sep 14, 2023 9:14 am 0 Previous Close $17.00 Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is... (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will · Neumora ...Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study. Nov 28. Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million. Sep 16. Earnings and Revenue Growth Forecasts. NasdaqGS:NMRA - Analysts future estimates and past financials data (USD Millions) DateNeumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th.

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...Amneal Pharmaceuticals Stock (NYSE: AMRX) stock price, news, charts, stock research, profile.Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for ...The stock is expected to list on the Nasdaq under the ticker symbol “NMRA.” J.P. Morgan, BofA Securities, Guggenheim Securities, RBC Capital Markets and William Blair are the underwriters. The ...

NASDAQ:NMRA; Company Type For Profit. Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain ...20 Nov 2023 ... NMRA:NSQNASDAQ. Neumora Therapeutics Inc. Actions. Add to watchlist; Add ... Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, ...

Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ... NMRA Neumora Therapeutics Inc Form 8-K - Current report false 0001885522 0001885522 2023-11-01 2023-11-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT R...Neumora Therapeutics, Inc. (NMRA) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 12.13 +0.05 (+0.41%) At close: 04:00PM EST 11.90 -0.23 (-1.90%) After hours: 04:27PM EST 1d 5d... Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.The latest price target for CymaBay Therapeutics ( NASDAQ: CBAY) was reported by UBS on Tuesday, September 26, 2023. The analyst firm set a price target for 25.00 expecting CBAY to rise to within ...Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.(NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will · Neumora ...Atomera Inc (NASDAQ:ATOM)’s traded shares stood at 0.16 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $6.97, to imply an increase of 0.29% or $0.02 in intraday trading. The ATOM share’s 52-week high remains $10.72 ...

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA Get Free Report) traded up 4.6% on Friday . The stock traded as high as $11.21 and last traded at $11.09. 32,521 shares were traded during... Share to Feed. Insider Buying: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Major Shareholder Purchases 30,192 Shares of Stock Ticker Report • …

10 Okt 2023 ... Market Conditions: The broader stock market experienced a mixed situation on October 2, 2023. This can be attributed to concerns such as ...

Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... 27 Sep 2023 ... See the latest Neumora Therapeutics Inc stock price (NASDAQ:NMRA), related news, valuation, dividends and more to help you make your ...The latest price target for Harmony Biosciences ( NASDAQ: HRMY) was reported by Needham on Wednesday, November 1, 2023. The analyst firm set a price target for 53.00 expecting HRMY to rise to ...Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Visualize o gráfico de Neumora Therapeutics, Inc. ao vivo para acompanhar o movimento do preço de suas ações. Encontre previsões de mercado, NMRA finanças e notícias do mercado.Neumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.$8.11 +0.06 +0.75% Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease.WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...6 Wall Street analysts have issued 12-month price objectives for Neumora Therapeutics' stock. Their NMRA share price targets range from $18.00 to $26.00. On …

Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided ... (NMRA-140) is a highly selective, novel, …Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ... Instagram:https://instagram. futures paper tradinggeorge daniel watchelectric vehicle battery stockbiberk commercial auto insurance reviews A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …(NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will · Neumora ... best mobile app for futures tradingairplane insurance companies Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to NASDAQ Composite Index Sep. 18: CI Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million. ... (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist in Phase 3 development as a potential monotherapy treatment for …NVDA. NVIDIA Corporation Common Stock. $439.00 -16.81 -3.69%. Find the latest historical data for Nemaura Medical, Inc. Common Stock (NMRD) at Nasdaq.com. top asset management firms Which Neumora Therapeutics insiders have been buying company stock? The following insiders have purchased NMRA shares in the last 24 months: Amgen Inc ($29,999,985.00), Arch Venture Partners Xii, Llc ($2,626,582.57), Henry O Gosebruch ($189,300.00), and Kristina Burow ($28,803,319.17)./EIN News/ -- WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development ...